androgen deficiency
Endocrinology · 2005–2018
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| testosterone Treatment of androgen deficiency in adult males, and for micropenis, pubertal induction, and constitutional delay of growth or puberty in patients under 18… | Nov 2018 | Recommended with restriction | none received |
| testosterone Androgen deficiency; micropesis; pubertal induction; constitutional delay of growth or puberty. This submission specifically requested changes to restrictions… | Jul 2015 | Recommended with restriction | 7 individuals Western Sydney Transgender Support Group · Association for Transgender Health · Public Health Association Australia |
| testosterone Treatment of androgen deficiency in males with established pituitary or testicular disorders, males aged 40 years or older with confirmed androgen deficiency,… | Mar 2015 | Recommended with restriction | none received |
| testosterone Treatment of androgen deficiency in males, including those with established pituitary or testicular disorders, males aged 40 years or older with demonstrated… | Mar 2015 | Recommended with restriction | none received |
| testosterone Androgen deficiency in males with established pituitary or testicular disorders; androgen deficiency in males aged 40 years and older without established… | Jul 2014 | Recommended | no section in document |
| testosterone Androgen deficiency in males, including those with established pituitary or testicular disorders, males 40 years and older with confirmed testosterone… | Nov 2011 | Recommended with restriction | no section in document |
| testosterone undecanoate Testosterone replacement therapy in primary and secondary male hypogonadism, including androgen deficiency in males with established pituitary or testicular… | Nov 2005 | Recommended with restriction | no section in document |
Who spoke
Western Sydney Transgender Support Group · Association for Transgender Health · Public Health Association Australia
What the PBS pays
$17M in government benefit over 2024–25, across 212,326 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| testosterone undecanoate | $8.7M |
| testosterone | $8.1M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 5 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.